Figure 5个  Table 5
    • Control(n = 12) HIV-positive
      Treatment naïve (n = 22) First-line cART treated (n = 15) Second-line cART treated (n = 18)
      Age (years) 49 (32–54) 36 (30–42) 37 (31–45) 34 (28–49)
      Gender (male/female) 5/7 10/12 5/10 2/16
      Data presented as medians (interquartile ranges). These data are for specific samples used for Treg marker analyses in this study. Refer to Teer et al. (2019) for the complete sample set. cART: combination antiretroviral therapy.

      Table 1.  Study participant characteristics.

    • Treatment naïve First line cART treated Second line cART treated
      CD4 count (cells/μL) 503 (297–677) 337 (192–711) 364 (154–521)
      Viral load (C/mL) 586 (40–18,855) 582 (20–85,076) 4524 (69–109,383)
      Data presented as median (IQR). These data are for specific samples used for Treg marker analyses in this study. Refer to Teer et al. (2019) for the complete sample set. cART: combination antiretroviral therapy; C/mL: copies per millilitre.

      Table 2.  CD4 count and viral load in HIV-positive study participants.

    • CD4+CD25-FOXP3+ (%) CD4+CD25++FOXP3+ (%)
      CD4+CD25-GARP+ (%) r = 0.57; P < 0.0001 r = 0.37; P = 0.001
      CD4+CD25++GARP+ (%) r = 0.38; P = 0.0005 r = 0.24; P = 0.02
      CD4 count (cells/μL) r = - 0.53; P < 0.0001 r = - 0.38; P = 0.001
      Viral load (copies/mL) r = 0.43; P = 0.0007 r = 0.23; P = 0.04
      CD8+CD38+ (%) r = 0.21; P = 0.04 NS

      Table 3.  Correlation of CD25- and CD25++ Tregs expressing FOXP3 with immunological markers.

    • CD25-SATB1+ (%)
      CD8+CD38+ (%) r = 0.50; P < 0.0001
      CD8+CD142+ (%) r = 0.24; P = 0.02
      Plasma D-dimer (μg/mL) r = 0.24; P = 0.03

      Table 4.  Correlation of CD25- immunological markers.

    • IL-10 (pg/mL)
      CD4+CD25-FOXP3+ (%) r = 0.27; P = 0.03
      CD8+CD38+ (%) r = 0.50; P < 0.0001
      Plasma D-dimer (μg/mL) r = 0.24; P = 0.03

      Table 5.  Correlation of IL-10 with CD25- Tregs expressing FOXP3, immune activation of CD8+ T cells and plasma D-dimer.